At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 239 enrolled
Drug / intervention
NXN-188 +2 moredrug
Likely dose
NXN-188 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura
In Brief
A Phase 2 clinical trial evaluating NXN-188, placebo, and 1 other intervention for Migraine With Aura. Completed, enrolled 239 participants across 16 sites.
Detailed Summary
NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine With Aura
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJun 2009
Primary CompletionMar 2010
TodayJul 2026
First PostedJun 15, 2009
Enrollment StartJun 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.0 years ago
Interventions
NXN-188drug
NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
placebodrug
administered as 3 placebo hard gelatin capsules
sumatriptan succinatedrug
administered in a hard gelatin capsule with 2 capsules of placebo